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Young twigs and leaves of Caesalpinia bonduc (Linn) Roxb is used in the Southwestern part of Nigeria, as an 
antimalarial medicinal decoction together with other medicinal plant. In order to discover new antimalaria drug or 
drug lead and also to verify the traditional use of C. bonduc in this area, the in vitro antiplasmodial activity of crude 
extract, solvent fractions and compounds isolated from C. bonduc were investigated. In vitro antiplasmodial 
evaluation was carried out using chloroquine sensitive strain of Plasmodium falciparum FCR-3 and selective 
toxicity determination was investigated using sensitivity study on Mouse mammary tumor FM3A cells as a host 
model. Ethyl acetate and petroleum ether soluble solvent fractions of C. bonduc showed antiplasmodial activity with 
EC50 values of 16 and 18 µg/mL and selectivity index (SI) of 0.69 and 0.29 respectively. Bioassay guided 
fractionation of C. bonduc led to the isolation of seven flavonoids, 7-hydroxy-4'-methoxy-3,11-
dehydrohomoisoflavanone (1), 4,4'-dihydroxy-2'-methoxy-chalcone (2), 7,3'-dihydroxy-3,11-
dehydrohomoisoflavanone (3), Luteolin (4), quercetin-3-methyl ether (5), Kaempferol-3-O-β-D-xylopyranoside (6) 
and Kaempferol-3-O-α-L-rhamnopyranosyl-(1→2)-B-D-xylopyranoside (7). Structures of compounds 1 to 7 were 
elucidated by spectroscopic methods. Compound 2 exhibited moderate antiplasmodial activity with EC50 and SI 
values of 33 µM and 0.33 respectively while compounds 1, 3 to 7 showed insignificant antiplasmodial activity. The 
investigation revealed that the moderate antiplasmodial activity exhibited by the solvent fractions of C. bonduc 
might be mediated by 4,4'-dihydroxy-2'-methoxy-chalcone.   
 





Malaria remains a major parasitic disease in many tropical and subtropical regions of the world [1]. It appears to be 
the most prevalent of human diseases, especially in these areas and as such constitutes a major public health hazard. 
In 2010, an approximated 3.3 billion individuals were at risk of malaria, with majority of the population from people 
living in sub-Saharan Africa [2]. Pregnant women and children under the age of five living in Sub-Saharan Africa 
are the most severely affected groups in the population [3, 2]. In 2010, it was estimated that 91 % deaths have 
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occurred in WHO African region, in children below 5 years of age and pregnant women with malaria cases [4, 1]. 
As a result of its associated high morbidity and mortality, concerted research efforts are currently being channeled 
into the eradication of the disease across the globe [5].  
 
Caesalpinia bonduc, (family: Caesalpiniaceae, genus Fabaceae), commonly known as Gray Nicker nut (English) 
and Ayó (Yoruba), is a prickly shrub with grey, hard, globular shaped seeds with a smooth shining surface [6]. It is a 
medicinal plant predominantly distributed in the tropical and subtropical regions of Africa, Asia and the Caribbean 
[7]. It has a lot of applications in folk medicine. For instance, the pharmacological screening of the plant extracts 
reveals their anticancer, antimalarial, antihyperglycemic, anti-inflammatory, antirheumatic, anticonvulsant, anti-
measles and antipyretic activities [8, 9, 10, 11].  
 
The phytochemical analysis of the plant shows that it contains saponins, alkaloids, flavonoids, triterpenoids, 
diterpenoids, tannins and steroids [12, 13]. Detailed toxicological studies of the leaves and young twigs of the plant 
have been previously reported from our laboratory [14]. A survey of published works revealed the isolation of two 
phytochemicals with antiplasmodial activity from the seeds of C. bonduc [15, 16]. As a result of the antimalarial 
activity of the extract of C. bonduc [17], its dearth of information and the established usage of the plant in the 
southwestern part of Nigeria as an antimalarial decoction [personal communication, 2009], we attempted to screen 
the solvent extracts and the isolated compounds from the young twigs and leaves of C. bonduc for their antimalarial 
activity. This paper reports the in vitro antiplasmodial activity of tested compounds and extract against P. 




2.1. Plant material  
Young twigs and leaves of C. bonduc (Linn) Roxb. were collected from Forestry Research Institute of Nigeria 
(FRIN), Ibadan, Oyo state, Nigeria. Plant identification was done by Dr.  Conrad Omonhinmi, Department of 
Biological Sciences, College of Science and Technology, Covenant University, Ota, Ogun state, Nigeria. 
Authentication and voucher referencing were carried out at FRIN with voucher specimen SHI108408 deposited in 
their Herbarium.  
 
2.2 Other experimental materials 
All reagents used were of analytical grades. Antimalarial agents, quinine hydrochloride, pyrimethamine and 
artemisinin, were purchased from Sigma (St. Louis, MO, U.S.A.). P. falciparum ATCC 30932, FCR-3 strain was 
used as a malaria parasite in this study. It was cultivated by a modification of the method of Trager and Jensen [18, 
19] using a 5 % hematocrit of type A human red blood cells suspended in RPMI 1640 medium and supplemented 
with heat-inactivated 10 % type A human serum. Mouse mammary tumor FM3A cells (wild-type, subclone F28-7) 
were maintained in a suspension culture at 37 °C in a 5 % CO2 atmosphere in plastic bottles containing ES medium 
supplemented with 2 % heat-inactivated fetal bovine serum [20].  
 
2.3. Extraction and solvent fractionation of plant material  
The leaves and young twigs of the plant collected were air dried at room temperature and powdered. Powdered plant 
(8.8 kg) was extracted with 75 % v/v ethanol (50 L), at normal room temperature (25 OC), by maceration for 72 
hours using three consecutive extractions. The total filtrate was concentrated to dryness with rotary evaporator at 50 
oC. The dried ethanolic extract of the plant (1120 g) was re-suspended in distilled water (H2O) and partitioned in 
sequence with petroleum ether, ethyl acetate and n-butanol. The different solvent fractions were concentrated with 
rotary evaporator to yield petroleum ether - soluble fraction (150 g), ethyl acetate - soluble fraction (120 g), n-
Butanol - soluble fraction (170 g), and H2O - soluble fraction (630 g).  Crude fraction and each of the soluble solvent 
fractions were subjected to biological determination.  
 
2.4. Fractionation, isolation and identification of compounds  
Ethyl acetate and petroleum ether soluble fractions were combined (270 g) and separated by column 
chromatography (CC) (3 kg silica gel, mesh 100-200; solvent: chloroform-methanol (100:1)). Fractions were 
collected in gradient and this afforded 20 different fractions (C1 to C20). Successive column separations of C6 in 
(Silica gel, mesh 200 – 300; solvent: petroleum ether-acetone (15:1)) and (silica gel, mesh 10 – 40; solvent: 
chloroform-ethyl acetate (30:1)) afforded compound 1. Successive CC separation of C10 on (silica gel, mesh 200 – 
300; solvent: chloroform-acetone (30:1)); (Silica gel, mesh 200 – 300; solvent: chloroform-methanol (120:1)); and 
(silica gel, mesh 10 – 40; solvent: chloroform-methanol (60:1)) and further separation by HPLC (column: YMC-
Pack ODS-A, 10 mm × 15 cm, flow rate of 2 ml/min; solvent: methanol-water (60: 40) and (58: 42) led to the 
separation of compounds 2 and 3 respectively. Series of CC separation of C12 on (silica gel, mesh 200 – 300; 
solvent: chloroform-methanol (200:1)); (silica gel, mesh 10 – 40; solvent: chloroform-methanol (40:1)); (sephadex 
Olubanke O. Ogunlana et al                 J. Chem. Pharm. Res., 2015, 7(1):931-937 
______________________________________________________________________________ 
933 
LH-20, solvent: chloroform-methanol (1:1)) and further separation by HPLC (YMC-Pack ODS-A, 10 mm × 15 cm, 
flow rate of 2 ml/min; MeOH: H2O (50: 50)) led to the separation of compounds 4 and 5. Sequential separation of 
C16 by CC on (Sephadex LH-20, solvent: chloroform-methanol (1:1)); (silica gel, mesh 10 – 40; chloroform-
methanol (20:1)) and separation by HPLC (YMC-Pack ODS-A, 10 mm × 15 cm, flow rate of 2 ml/min; solvent: 
methanol-water (47: 53)) afforded compound 6. Sequential CC separation of C20 in (Sephadex LH-20; solvent: 
chloroform-methanol (1:1)); MPLC (RP – 18; MeOH: solvent: water (10 – 90 %)) and HPLC (YMC-Pack ODS-A, 
10 mm × 15 cm, flow rate of 2 ml/min; solvent: methanol-water (60:40)) afforded compound 7. Structural 
identification was carried out by spectroscopic methods.  
 
2.5. In vitro antimalarial activity determination 
Various concentrations of extract, solvent fractions and isolated compounds including positive control samples 
(quinine hydrochloride, pyrimethamine and artemisinin) were prepared in dimethyl sulfoxide (DMSO) or water 
(H2O). An aliquot of each sample solution (10 µL) was added to an individual well of a 24-well multi-dish. 
Erythrocytes with 0.3 % parasitemia were added to each well containing 990 µL of culture medium to give a final 
hematocrit level of 3 %. The plates were incubated at 37 °C for 72 hrs in a multigas incubator (5 % CO2, 5 % O2, 90 
% N2 atmosphere). To evaluate the antimalarial activity of samples, thin blood films from each culture were 
prepared and stained with Giemsa. A total of 10000 erythrocytes per one thin blood film were examined under a 
microscope. All of the tested samples were assayed in duplicate at each concentration. Drug-free control cultures 
were ran simultaneously. The level of parasitemia in control was between 4 - 5 % at 72 hrs [21]. The parasitemia 
activity of samples were presented as EC50 values, which is the concentration of sample necessary to inhibit the 
increase in parasite density at 72 hrs by 50 % of the control. 
 
2.6. In vitro selective toxicity determination 
FM3A cells grew with a doubling time of about 12 hrs. Prior to exposure to drugs, the cell density was adjusted to 
5×104 cells/ml. A cell suspension of 990 µL was dispensed to the test plate and 10 µL of the samples at various 
concentrations suspended in DMSO or H2O were added to individual wells in a 24-well multi-dish. The plates were 
incubated at 37 °C in a 5% CO2 atmosphere for 48 hrs. All of the tested samples compounds were assayed in 
triplicate at each concentration. Cell numbers were measured using a cell counter CC-130 [21]. The samples’ 
selective toxicity were presented as EC50 values, which refers to the concentration of the sample necessary to inhibit 
by 50% the increase in cell density of the control at 48 hrs. Selectivity values (the EC50 value for FM3A cells per the 
EC50 value for P. falciparum) were calculated as follows: 
 
Selectivity: EC50 value of FM3A cell / EC50 value of P. falciparum 
 
RESULTS AND DISCUSSION 
 
From the bioactive guided fractionation of ethylacetate and petroluem ether solvent fractions of C. bonduc, seven 
flavonoids (Compounds 1 to 7) were obtained. Compound 1 was separated as a pale yellow crystalline solid with 
yield of 319.30 mg. Its chemical formula was ascertained to be C17H14O4, on the ground of the molecular ion peak of 
positive ESI-MS m/z 305 [M+Na]+. Compound 1 was elucidated as 7-hydroxy-4'-methoxyl-3,11-
dehydrohomoisoflavanone (Figure 1). The 1D 1H and 13C NMR spectra data (Table 1) were in accord with published 
work [22]. Compound 2 was separated as a pale yellow powder with yield of 15.60 mg. Its chemical formula was 
ascertained to be C16H14O4, on the ground of the molecular ion peaks of positive ESI-MS m/z 271 [M+H]+ and 293 
[M+Na]+. Compound 2 was identified as 4,4'-dihydroxy-2'-methoxy-chalcone (Figure 1). Its 1D 1H and 13C NMR 
spectra data (Table 2) were in accord with published work [23]. Compound 3 was separated as a pale yellow powder 
of 10.4 mg yield. Its chemical formula was observed to be C16H12O4, on the ground of the molecular ion peak of 
positive ESI-MS m/z 269 [M+H] +. Compound 3 was identified as 7,4'-dihydroxy-3,11-dehydrohomoisoflavanone 
(Figure 1). The 1H and 13C NMR spectra data (Table 1) were marked with close similarity with those of compound 
1. The data were in agreement with published work [24].  
 
Compound 4 was separated as a pale yellow powder like compounds 2 and 3 with yield of 12.80 mg. Its chemical 
formula was observed as C15H10O6 from its molecular ion peak at positive ESI-MS m/z 287 [M+H]+. Compound 4 
was elucidated as Luteolin (Figure 1). The 1H and 13C NMR spectra data (Table 3) were in accord with published 
work [25]. Compound 5 was separated as a pale yellow crystalline solid with yield of 227.00 mg. Its chemical 
formula was observed to be C16H12O7, on the ground of the chemical ion peak at positive ESIMS m/z 317 [M+H]+. 
Compound 5 was elucidated as quercetin-3-methyl ether (Figure 1). The 1H and 13C NMR spectra data (Table 3) 
were in accord with published work [26].  
 
Compound 6 was separated as a brown paste with yield of 24.40 mg. Its chemical formula was observed to be
 
C20H18O10, on the ground of the molecular ion peak at positive ESI-MS m/z 441 [M+Na]+. Compound 6 was 
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elucidated as kaempferol-3-O-β-D-xylopyranoside (Figure 1). The 1H and 13C NMR spectra data (Table 4) were in 
accord with published work [27]. Compound 7 was separated as a pale yellow crystalline solid like compounds 1 
and 5, with yield of 79.50 mg. Its chemical formula was observed to be C26H28O14, on the ground of the molecular 
ion peak at positive ESIMS m/z 565 [M+H]+. Compound 7 was identified to be Kaempferol-3-O-α-L-
rhamnopyranosyl-1→2)-β-D-xylopyranoside (Figure 1). The 1H and 13C NMR spectra data were (Table 4) in accord 
with published work [28].  
 
Figure 1 illustrates the chemical structures of compounds 1-7. Compounds 1-7 were identified and reported as 
follows, 7-hydroxy-4'-methoxy-3,11-dehydrohomoisoflavanone (1), 4,4'-dihydroxy-2'-methoxy-chalcone (2), 7,3'-
dihydroxy-3,11-dehydrohomoisoflavanone (3), Luteolin (4), quercetin-3-methyl ether (5), Kaempferol-3-O-β-D-
xylopyranoside (6) and Kaempferol-3-O-α-L-rhamnopyranosyl-(1→2)-B-D-xylopyranoside (7).  
 
The results of the in vitro antimalarial activity and selectivity index determination of the ethanolic extract, solvent 
fractions and compounds isolated from C. bonduc are summarised in Table 5. Petroleum ether and ethyl acetate 
solvent fractions exhibited moderate antimalarial activities with EC50 values of 18 and 16 µg/ml and selectivity 
index of 0.29 and 0.69 respectively. Among the isolated compounds, only 4,4'-dihydroxy-2'-methoxy-chalcone (2) 
exhibited moderate antimalarial activity with EC50 values of 33 µM and selectivity index of 0.33 (Table 5), on the 
other hand, the EC50 values of compounds 1, 3 to 7 did not showed antimalarial activity.  
 
The in vitro bioassay study of the ethanolic extract, solvent fractions and isolated compounds of C. bonduc, revealed 
its moderate antiplasmodial but poor selective activities, thus, indicating a non-selective antimalarial activity of C. 
bonduc. In spite of the less beneficiary antiplasmodial activity of flavonoids as a result of their poor selective index, 
the in vitro antiplasmodial activity of exiguaflavanone A and B,  from Artemisia indica [29], (−)-cis-3-acetoxy-
4′,5,7-trihydroxyflavanone, from Siparuna andina [30], 6-Hydroxyluteolin-7-O-(1″-α-rhamnoside) [31], calycosin 
and genistein [32] have been reported. However, this is the first report of flavonoid isolated from C. bonduc with 
moderate antiplasmodial activity. Although, the exact antiplasmodial action of flavonoids is unknown but they have 
been shown to inhibit the influx of L-glutamine and myo-inositol into infected erythrocytes [33]. The ability of 
flavonoids to form reactive oxygen species has also been linked to their antiplasmodial activity [34]. Lack of 
defense mechanisms against oxidative stress in P. falciparum makes the parasite susceptible to drugs with ability of 
generating reactive oxygen species [35]. Chalcones are suggested to have potential for the development of 
inexpensive antimalarials [36]. The antiplasmodial activity of young twigs and leaves of C. bonduc has been linked 
to the possession as 4,4'-dihydroxy-2'-methoxy-chalcone (2) has one of its bioactive constituents.   
 
Table I 1H and 13C-NMR spectral data for compounds 1 and 3 (δ in ppm, J in Hz) 
 
   δC  δH   δC  δH 
Compounds  1     3 
2  67.53  5.35 (2H, d, J = 1.5)  69.05  5.35 (2H, br, s) 
3  126.50  -   127.07  - 
4  179.52  -   183.06  - 
5  129.39  7.73 (1H, d, J = 8.5)  130.69  7.80 (1H, d, J = 8.0) 
6  111.13  6.54 (1H, dd, J = 8.5, 2.0) 112.16  6.52 (1H, d, J = 8.0) 
7  164.61  -   166.69  - 
8  102.41  6.31 (1H, d, J = 2.0)  103.60  6.31 (1H, br, s) 
9   162.47  -   164.85  - 
10  114.30  -   115.90  -   
11  135.21  7.63 (1H, br, s)  138.16  7.71 (1H, s) 
1'  128.82  -   129.56  - 
2'  132.19  7.39 (2H, d, J = 8.5)  133.50  7.25 (2H, d, J = 7.6) 
3'  114.23  7.04 (2H, d, J = 8.5)  116.70  6.88 (2H, d, J = 7.6) 
4'  160.26  -   160.53  - 
5'  114.23  7.04 (2H, d, J = 8.5)  116.70  6.88 (2H, d, J = 7.6) 
6'  132.19  7.39 (2H, d, J = 8.5)  133.50  7.25 (2H, d, J = 7.6) 
4'-OCH3  55.33  3.81 (3H, s)   -  - 
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Table 2 1H and 13C-NMR spectral data for compound 2 (δ in ppm, J in Hz) 
 
  δC  δH     
Compounds  2       
1  128.04  - 
2  131.38  7.50 (2H, d, J = 8.4)   
3  116.87  6.82 (2H, d, J = 8.4)     
4  161.21  -     
5  116.87  6.82 (2H, d, J = 8.4)   
6  131.38  7.50 (2H, d, J = 8.4)   
7  144.16  7.56 (1H, d, J = 15.6)     
8  125.07  7.41 (1H, d, J = 15.6)   
9   193.16  -     
1'  121.76  -     
2'  162.53  -   
3'  100.11  6.51 (1H, br s)   
4'  164.49  -     
5'  108.91  6.45 (1H, d, J = 8.4)   
6'  133.73  7.57 (1H, d, J = 8.4)   
2'-OCH3  56.14  3.88 (3H, s)    
1H NMR and 13C NMR were recorded at 500 and 125 MHz respectively in DMSO-d6. 
 
Table 3 1H and 13C-NMR spectral data for compounds 4 and 5 (δ in ppm, J in Hz) 
  δC  δH    δC  δH 
Compounds  4      5 
2  166.00  -    158.0  - 
3  103.82  6.54 (1H, s)   139.52  - 
4  183.85  -    180.01  - 
5  163.19  -    163.08  - 
6  100.09  6.20 (1H, d, J = 1.2)   99.75  6.20 (1H, d, J = 2.0)  
7  166.33  -    165.94  - 
8  94.97  6.44 (1H, br s)   94.70  6.39 (1H, d, J = 2.0) 
9   159.40  -    158.42  - 
10  105.28  -    105.83  -   
1'  123.64  -    122.88  - 
2'  114.11  7.38 (1H, overlap)   116.42  7.63 (1H, d, J = 2.0) 
3'  147.11  -    146.50  - 
4'  150.98  -    149.97  - 
5'  116.75  6.90 (1H, d, J = 8.4)   116.42  7.53 (1H, dd, J = 8.4) 
6'  120.28  7.38 (1H, overlap)   122.31  6.90 (1H, d, J = 8.4) 
3-OCH3  -  -    60.52  3.78 (3H, s) 
1H NMR and 13C NMR were recorded at 500 and 125 MHz respectively in DMSO-d6. 
 
Table 4 1H and 13C-NMR spectral data for compounds 6 and 7 (δ in ppm, J in Hz) 
  δC  δH    δC  δH 
Compounds  6      7 
2  158.38  -    158.12  - 
3  135.31  -    134.30  - 
4  179.36  -    179.12  - 
5  163.00  -    162.90  - 
6  99.89  6.18 (1H, br s)   99.82  6.06 (1H, br s)  
7  165.96  -    165.50  - 
8  94.76  6.37 (1H, br s)   94.71  6.24 (1H, br s) 
9   15890  -    158.54  - 
10  105.61  -    105.80  -   
1'  122.58  -    122.90  - 
2'  132.20  8.01 (2H, d, J = 8.4)   132.01  7.92 (2H, d, J = 8.,5) 
3'  116.11  6.86 (2H, d, J = 8.4)   116.12  6.82 (2H, d, J = 8.5) 
4'  161.60  -    161.23  - 
5'  116.11  6.86 (2H, d, J = 8.4)   116.12  6.82 (2H, d, J = 8.5) 
6'  132.20  8.01 (2H, d, J = 8.4)   132.01  7.92 (2H, d, J = 8.,5) 
1''  104.64  5.16 (1H, d, J = 6.8)   101.22  5.53 (1H, d, J = 7.0) 
2''  75.33  3.74 (1H, d, J = 4.8)   79.32  - 
3''  77.52  3.48 (1H, t, J = 5.8)   77.90  - 
4''  70.98  3.41 (1H, d, J = 8.2)   72.22  - 
5''  67.20  3.76 (2H,s, J = 4.6)   66.90  - 
1'''  -  -    102.53  5.21 (1H, br s) 
2'''  -  -    71.34  - 
3'''  -  -    72.33  - 
4'''  -  -    74.01  - 
5'''  -  -    70.01  - 
6'''  -  -    17.73  - 
1H NMR and 13C NMR were recorded at 500 and 125 MHz respectively in DMSO-d6. 
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Table 5 Antimalarial activity and selectivity assay results of extracts and isolated compounds from of C. bonduc 
 
Extracts/Compound  aEC50 (µg/mL, µM)  bEC50 (µg/mL, µM) cSelectivity   
Ethanol extract   >92.0±0.04 (51 %) 36.0±0.08  0.39 
Petroleum ether extract 18.0±0.02  5.2±0.08  0.29 
Ethyl acetate extract  16.0±0.01  11.0±0.08  0.69  
n-Buthanol extract  >90.0±0.08  (76%) >90.0±0.08 (80%) 1.0   
Water extract  >62.0±0.06 (82%) >62.0±0.08 (68%) 1.0  
1   >27.0±0.08 (64%) 8.8±0.03  0.33 
2   33.0±0.01  11.0±0.03    0.33 
3    >27.0±0.03 (61%) 11.0±0.04   0.41 
4   >25.0±0.02 (58%) 5.4.0±0.03    0.2 
5   >9.8.0±0.03 (99%) 0.56±0.03   0.06 
6   >9.7.0±0.02 (100%) >9.7±0.03 (88 %) 1.0 
7   >5.7.0±0.03 (95%) >5.7±0.03 (97 %) 1.0 
Quinine   0.2±0.02  100.0±0.01 500.0 
Pyrimethamine  0.001±0.01 0.1±0.02  100.0 
Artemisinin  0.01±0.04  9.0±0.02  900.0  
 
Values in parenthesis show the growth inhibition (%) of some doses. EC50 is effective concentration of sample 
necessary to inhibit the increase in parasite density at 72 hrs by 50 % of the control. EC50 is expressed as “µg/mL” 
for extract and as “µM” for isolated compounds. aChloroquine sensitive strain (FCR-3) of P. falciparum, bMouse 
mammary tumor FM3A cells representing a model of host, cSelective toxicity is calculated as EC50 value for FM3A 
cells/EC50 for P. falciparum.  
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